GHK-Cu Compounding Pharmacy: Research-Only vs Medical-Grade Peptides Explained

Is 'Medical-Grade' GHK-Cu an FDA Category?

No. No FDA-approved drug is known to contain GHK-Cu; FDA treats it as a nominated bulk drug substance for compounding, not an approved medicine [1]. A copper peptide product may be a cosmetic, a compounded drug, or an unapproved injectable that FDA lists as nominated but withdrawn, and what 'medical-grade' means depends on which of these it is [1][2][3].

The copper drug that does hold an approval is a different compound. Zycubo (copper histidinate) was approved on January 12, 2026 for Menkes disease in children; copper histidinate is not the GHK copper complex [4].

What 'Research-Only' Actually Means

A 'research use only' label by itself does not make a product a cosmetic or an FDA-approved drug. Under the FD&C Act, intended use is what separates a cosmetic from a drug: claims to treat or prevent disease, or to change the structure or function of the body, make a product a drug, and cosmetic ingredients other than color additives do not need FDA approval before sale. FDA looks at how a product is marketed, including its labeling, advertising and other claims [2].

Cosmetic Copper Peptide Creams and Serums

Skin-care serums and creams with copper peptide are sold as cosmetics, and whether a product is a cosmetic or a drug depends on its intended use and marketing claims [2]. Strength is set by the manufacturer and is not FDA-reviewed; the one drug-style human trial found used a 0.4% tripeptide copper complex cream [7].

A topical can cross into drug territory. FDA gives claims to restore hair growth, reduce cellulite or regenerate cells as examples that make a product a drug [2]. One sunscreen with GHK-Cu in its name lists UV filters, not GHK-Cu, as its active ingredients [8].

For information about a topical copper peptide product, see copper peptide cream.

Compounded GHK-Cu From a State-Licensed Pharmacy

Non-injectable GHK-Cu is on the list FDA maintains for state-licensed pharmacies and physicians. 'GHK-Cu (except for injectable routes of administration)' is in category 1 — the group FDA is evaluating for the compounding bulks list — and FDA says it generally does not intend to act against compounders of category 1 substances when the conditions in its guidance are met [1][5].

The listing moved twice in 2026. GHK-Cu was removed from category 1 on April 22, 2026 when the nominations were withdrawn; on May 5, 2026 a nominator clarified it had withdrawn only the injectable route, and FDA added non-injectable GHK-Cu back to the list, updated May 14, 2026 [1][5]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee about whether GHK-Cu belongs on the bulks list before the end of February 2027; no vote has happened [1].

FDA's page says bulk substances used by state-licensed pharmacies and physicians in compounding must be accompanied by a valid certificate of analysis and manufactured by an establishment registered with FDA [5]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [6].

Injectable GHK-Cu: A Different Status

FDA's page on bulk substances that may present significant safety risks, content dated 04/22/2026, lists 'GHK-Cu (for injectable routes of administration)' in its 'nominated but withdrawn' table. FDA's stated concern is that compounded injectable drugs containing GHK-Cu may pose a risk of immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations [3].

Injectable GHK-Cu is not in category 1, and not in any category on FDA's current list [1]. It also does not appear on FDA's list for outsourcing facilities, updated March 21, 2025 [9]. An injectable GHK-Cu product is not a cosmetic and is not FDA-approved [2].

What the HHS October 2026 Peptide Policy Did Not Cover

HHS's October 2026 draft enforcement-discretion policy names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [10]. GHK-Cu is not one of them.

What the Human Studies Show

The human trials found were topical and small to moderate in size; none tested an injectable product.

A randomized trial published in 2006 tested post-treatment skin care with or without GHK-Cu after CO2 laser resurfacing of the skin around the mouth; 13 patients completed it. Computer analysis and blinded evaluators found no significant difference in how quickly redness resolved, in wrinkles, or in overall skin quality. A patient questionnaire did show a significant difference in overall skin quality favoring GHK-Cu (P=.04) [11].

In a prospective randomized evaluator-blinded trial in venous stasis ulcers, 86 evaluable patients were compared across a 0.4% tripeptide copper complex cream, an inert vehicle placebo, and silver sulfadiazine 1%. The copper cream was no different from placebo on ulcer size; silver sulfadiazine reduced it [7].

A 2026 systematic review screened 1,247 records covering 2005 to 2026 and kept 64 for qualitative synthesis. Its authors describe the human literature as thin and fragmented, note that most randomized trials are small and run on facial cosmetic creams, and state that microneedle delivery of GHK-Cu has yet to be evaluated in a single registered, adequately powered human randomized controlled trial [12].

A narrative review by the researchers who proposed the peptide's actions reports collagen and proteoglycan stimulation, metalloproteinase modulation, attraction of immune and endothelial cells to injury, and faster wound healing in dogs, rats, mice and pigs, plus cosmetic effects such as firmer skin and fewer fine lines. These come from laboratory, animal and company-type data rather than randomized trials, and they are proposed mechanisms, not proven human effects [13].

What Differs Between Products

For a topical, the difference is regulatory category: cosmetics are not approved before sale, and the claims decide whether the product is legally a drug [2]. For a compounded non-injectable preparation, the difference is the pharmacy's position under category 1 and the fact that FDA has not reviewed the finished preparation [1][5][6]. For an injectable, FDA has approved no GHK-Cu injection and has published a specific immunogenicity concern [3].

Athletes have one more consideration. GHK-Cu is not named on WADA's 2026 Prohibited List or its 2027 List, but WADA's S0 class covers substances with no approval from any governmental health authority, and the 2027 notes say peptides not specifically named may still be prohibited — so the absence of the name is not a clearance [14][15].